Country: Canada
Language: English
Source: Health Canada
LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE)
PFIZER CANADA ULC
J01FF02
LINCOMYCIN
300MG
SOLUTION
LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE) 300MG
INTRAMUSCULAR
2ML
Prescription
LINCOMYCINS
Active ingredient group (AIG) number: 0105826002; AHFS:
CANCELLED POST MARKET
2016-05-06
_ _ _LINCOCIN (lincomycin hydrochloride) Product Monograph _ _Page 1 of 20_ PRODUCT MONOGRAPH PR LINCOCIN ® LINCOMYCIN INJECTION USP 300 MG/ML ANTIBIOTIC Pfizer Canada Inc. 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Preparation: 17 September 2003 Date of Revision: 8 June 2018 Control No. 208095 ® Pharmacia & Upjohn Company LLC Pfizer Canada Inc., Licensee Pfizer Canada Inc. 2018 _ _ _LINCOCIN (lincomycin hydrochloride) Product Monograph _ _Page 2 of 20_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE ....................................................................................... 3 CONTRAINDICATIONS ............................................................................................................. 3 WARNINGS AND PRECAUTIONS ........................................................................................... 4 ADVERSE REACTIONS .............................................................................................................. 6 DRUG INTERACTIONS .............................................................................................................. 7 DOSAGE AND ADMINISTRATION .......................................................................................... 7 OVERDOSAGE ............................................................................................................................. 8 ACTION AND CLINICAL PHARMACOLOGY ...................................................................... 8 STORAGE AND STABILITY ...................................................................................................... 9 DOSAGE FORMS, COMPOSITION AND PACKAGING....................................................... 9 PART II: SCIENTIFIC INFORMATION .............................................................................. 10 PHARM Read the complete document